Szmu Pharma is deciding whether to proceed with Phase 3 of clinical trials for a new Asthma drug.  So far �3bn has been spent on Phase 1 and 2.  Estimate that Phase 3 will cost �3.4bn, take 4 years and have an 80% chance of success.  Should the company proceed?